<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="115996">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01907568</url>
  </required_header>
  <id_info>
    <org_study_id>UH-1</org_study_id>
    <secondary_id>NL42959.041.13</secondary_id>
    <nct_id>NCT01907568</nct_id>
  </id_info>
  <brief_title>Understanding Hallucinations (Part I)</brief_title>
  <acronym>UH-1</acronym>
  <official_title>Understanding Hallucinations (Part I) - Phenomenology and Cognition</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UMC Utrecht</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Universitair Medisch Centrum Groningen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Free University Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Parnassia Bavo Groep</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>UMC Utrecht</source>
  <oversight_info>
    <authority>Netherlands: Medical Ethics Review Committee (METC)</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Psychotic symptoms (hallucinations and delusions) are present in several psychiatric and
      neurological disorders as well as in the general population. Effective treatment strategies
      for these symptoms in all patients are lacking and treatment-response can presently not be
      predicted. To date, the exact pathophysiological mechanism of these symptoms remains
      unknown. By investigating (subtypes) of hallucinations and delusions in all populations, a
      common pathway may be found, leading to more effective treatment options. Alternatively,
      different subtypes may be associated with different pathophysiological mechanisms.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Anticipated">June 2017</completion_date>
  <primary_completion_date type="Anticipated">June 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Case Control, Time Perspective: Cross-Sectional</study_design>
  <primary_outcome>
    <measure>The number of clusters of patients with shared symptom profiles as determined by latent class analysis, and the difference in scores on cognitive assessment between these identified clusters.</measure>
    <time_frame>Three years</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>The internal consistency, test-retest reliability, inter-rater reliability, criterion validity and construct validity of a newly developed questionnaire.</measure>
    <time_frame>Two years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The difference in scores on cognitive assessment between participant groups with and without psychotic symptoms.</measure>
    <time_frame>Three years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_groups>10</number_of_groups>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Hallucinations</condition>
  <condition>No Hallucinations</condition>
  <arm_group>
    <arm_group_label>Patients with schizophrenia</arm_group_label>
    <description>With and without hallucinations</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients with borderline personality disorder</arm_group_label>
    <description>With and without hallucinations</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients with hearing impairment</arm_group_label>
    <description>With and without hallucinations</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients with visual loss</arm_group_label>
    <description>With and without hallucinations</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients with Parkinson's Disease</arm_group_label>
    <description>With and without hallucinations</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients with Alzheimer's Disease</arm_group_label>
    <description>With and without hallucinations</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients with dementia with Lewy Bodies</arm_group_label>
    <description>With and without hallucinations</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients with Posttraumatic Stress Disorder</arm_group_label>
    <description>With and without hallucinations</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients with delirium</arm_group_label>
    <description>With and without hallucinations</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy participants</arm_group_label>
    <description>With and without hallucinations</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        We aim to include subjects of each of the following diagnostic groups, both with and
        without psychotic symptoms:

          1. patients with schizophrenia spectrum disorders

          2. patients with borderline personality disorder (BPD)

          3. patients with hearing impairment

          4. patients with visual loss

          5. patients with Parkinson's disease (PD)

          6. patients with Alzheimer's disease (AD)

          7. patients with Lewy Body dementia (DLB)

          8. patients with post-traumatic stress disorder (PTSD)

          9. patients with delirium

         10. healthy individuals
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age &gt; 18 years

          -  mentally competent

          -  in case of delirium: family member able to give informed consent

          -  Individuals with hallucinations will have to experience at least one episode of
             hallucinations over the last month.

        Exclusion Criteria:

          -  Age &lt;18)

          -  Participants that cannot read, speak or understand Dutch

          -  For all included diagnostic groups except delirium: Mentally incompetent individuals
             who are not capable to provide informed consent, as determined by their treating
             physician.

          -  For the control group: no (history of) hallucinations
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Iris Sommer, Prof, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UMC Utrecht</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Teus van Laar, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UMC Groningen</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Philip Scheltens, Prof, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>VU University Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Karin Slotema, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Parnassia Bavo Groep</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sanne Koops, Msc.</last_name>
    <phone>+31887558672</phone>
    <email>S.Koops@umcutrecht.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Remko van Lutterveld, Dr.</last_name>
    <email>R.vanLutterveld@umcutrecht.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>VU Medical Center</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Odile van den Heuvel, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Philip Scheltens, Prof.Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Odile van den Heuvel, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Evelien Lemstra, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Elizabeth Foncke, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Parnassia Bavo Groep</name>
      <address>
        <city>Den Haag</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Karin Slotema, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Karin Slotema, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UMC Groningen</name>
      <address>
        <city>Groningen</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Anne-Marthe Meppelink, MD</last_name>
    </contact>
    <investigator>
      <last_name>Teus van Laar, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anne-Marthe Meppelink, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UMC Utrecht</name>
      <address>
        <city>Utrecht</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sanne Koops, Msc.</last_name>
      <phone>+31 8858672</phone>
      <email>S.koops@umcutrecht.nl</email>
    </contact>
    <investigator>
      <last_name>Iris Sommer, Prof.Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Remko van Lutterveld, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sanne Koops, Msc.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Arjen Slooter, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>July 2013</verification_date>
  <lastchanged_date>July 22, 2013</lastchanged_date>
  <firstreceived_date>July 8, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>UMC Utrecht</investigator_affiliation>
    <investigator_full_name>Iris Sommer</investigator_full_name>
    <investigator_title>Prof.Dr.</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hallucinations</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
